A review of UHMWPE wear-induced osteolysis:the role for early detection of the i

Adrese M Kandahari,Xinlin Yang,Kevin A Laroche,Abhijit S Dighe,Dongfeng Panand Quanjun Cui

A review of UHMWPE wear-induced osteolysis:the role for early detection of the immune response

Adrese M Kandahari1,Xinlin Yang1,Kevin A Laroche1,Abhijit S Dighe1,Dongfeng Pan2and Quanjun Cui1

In a world where increasing joint arthroplasties are being performed on increasingly younger patients, osteolysis as the leading cause of failure after total joint arthroplasty(TJA)has gained considerable attention. Ultra-high molecular weight polyethylene wear-induced osteolysis is the process by which prosthetic debris mechanically released from the surface of prosthetic joints induces an immune response that favors bone catabolism,resulting in loosening of prostheses with eventual failure or fracture.The immune response initiated is innate in that it is nonspeci f i c and self-propagating,with monocytic cells and osteoclasts being the main effectors.To date,detecting disease early enough to implement effective intervention without unwanted systemic side effects has been a major barrier.These barriers can be overcome using newer in vivo imaging techniques and modules linked with f l uorescence and/or chemotherapies.We discuss the pathogenesis of osteolysis,and provide discussion of the challenges with imaging and therapeutics.We describe a positron emission tomography imaging cinnamoyl-Phe-(D)-Leu-Phe-(D)-Leu-Phe-Lys module, speci f i c to macrophages,which holds promise in early detection of disease and localization of treatment. Further research and increased collaboration among therapeutic and three-dimensional imaging researchers are essential in realizing a solution to clinical osteolysis in TJA.

INTRODUCTION

Total joint arthroplasty(TJA)is often considered one of the success stories of modern medicine,as it provides reliable long-term improvement in patient function,pain,and quality of life.1–8Aseptic loosening(AL)by periprosthetic osteolysis is the leading cause of failure after TJA4–6,9–10with reported incidence rates ranging from 10%to 70%.4–5,11–12The incidence of TJA is increasing,with over four million primary total hip/knee arthroplasties(THA,TKA)projected annually by 2030 in the United States and revision rates expected to double even earlier.13Patients under 65 years of age currently comprise over 40%of the population undergoing THA or TKA,with incidence among this age group expected to increase.7,14As more TJA is performed on increasingly younger patients,rates of osteolysisinduced AL will intensify,as young age is a known risk factor for osteolysis,TJA failure,and revision surgery.4,11,15Compared with primary THA or TKA,revision surgery has been shown to be costlier,technically more dif fi cult,and associated with higher rates of complications and inferior outcomes.8,15–19Considering this evidence,the vast impact TJA will have on US healthcare and economy in the near future quickly becomes evident.Although understanding of the mechanisms underlying osteolysis-induced AL has substantially improved in recent decades,barriers in the implementation of effective intervention obviating the need for revision surgery or minimizing its technical and fi nancial demands still exist.These barriers revolve around dif fi culties in localization:early detection as osteolysis is often asymptomatic or undiagnosed until the need for revision surgery,4,8,17,20and therapy that is both effective and speci fi c enough as to avoid intolerable or undesirable systemic side effects.5,8,21–22

Periprosthetic osteolysis is the process by which biological or mechanical forces initiate a local immune response in periprosthetic tissue that eventually results in implantloosening and failure.Although this could be due to a number of factors such as infection,wear-induced osteolysis is induced by wear particles mechanically released at the articulating surface of prostheses over time.The material and character of the prosthesis implanted have implications on this process4–7,9,15,22–23with research focusing on developing prostheses with decreased rates of wear and therefore osteolysis and AL.Ultra-high molecular weight polyethylene(UHMWPE)is a plastic bearing commonly utilized in TJA,as it is durable and has low antigenicity and well-established clinical success.7,15Recently,highly cross-linked UHMWPE has come into use, proven in vitro to decrease wear by up to 92%24with promising short-term in vivo results.15,25–27Despite these advances,long-term data are lacking and osteolysis will continue to be a burden for patients after TJA,especially as patients undergoing these procedures become younger and younger.Recent research has characterized an immune response dominated by cells of monocytic or osteoclastogenic lineage when challenged with UHMWPE wear particles;5–6,8,22,28–31the current study explores that response:its players,progression,and future direction for timely detection and intervention.

UHMWPE WEAR DEBRIS:AN INCITING FACTOR

Prostheses utilized in TJA serve to mimic the function of the natural joint and therefore face similar mechanical and chemical challenges:providing a smooth,durable,sliding surface that can afford suf f i cient and stable movement without pain over time.To attain the functional success of hyaline cartilage in vivo,prostheses must then balance the elements of friction,lubrication,and wear.4,32Wear refers to the loss of prosthetic material from the interface of articulating surfaces,and can be due to abrasion, adhesion,or fatigue.32This debris of wear particles deposits in periprosthetic tissue,eliciting a chain reaction that results in the phenomenon of osteolysis.

As the works of Revell et al.33and Mirra et al.34f i rst reported the associations between excessive polyethylene (PE)debris and loss of bone tissue and component loosening in 1978 and 1982,respectively;the presence of periprosthetic wear debris has been demonstrated to coincide with the diagnosis of osteolysis in countless models.8–9,28–29,31A dose-dependent response has been described between the two:as UHMWPE wear particles are increasingly generated,risk for osteolysis intensi f i es.35–36At the heart of this dose-dependent response thrives the macrophage with histographic cell counts positively correlating with amount of PE debris and bone resorption.28–29,31,37It logically follows that UHMWPE wear debris is capable of initiating an immune response mediated by macrophages,and this principle has led to the study of particulates and development of PE with unique properties in an attempt to circumvent this response.Schmalzried et al.37examined histological specimens from areas of bone resorption in 34 hips with radiographic evidence of periprosthetic bone loss and universally detected PE debris-laden macrophages regardless of pattern of bone loss,anatomic origin of specimen,or use of cement.PE particles were mostly intracellular and＜10 μm in length,with macrophage in f i ltration positively correlating with the amount of PE debris and degree of bone resorption observed.

Though highly variable,UHMWPE wear particulates generally range from 0.1 to 1.0 μm(average 0.5 μm)in length when recovered from the hip,but average～280 μm in length when recovered from the knee.6–7,31Particulates in the range of 0.1–1.0 μm are thought to be the most biologically active,with reported critical lengths of roughly 0.24–7.20 μm.6,31,38Green et al.38demonstrated that UHMWPE particulates measuring 0.24μm in length elicited the greatest rate of bone resorption and cytokine[tumor necrosis factor-α(TNF-α),interleukin(IL)-1β,IL-6,and prostaglandin E2(PGE2)]production in an in vitro mouse model at a particulate volume(μm3)to macrophage ratio of 10:1. When increasing the ratio to 100:1 the response dissipated; however,particulates measuring 0.45 and 1.71 μm in length then became active,paralleling their f i ndings in another similar study.39The work of these respective authors argues that wear debris incites a unique immune response dependent on both particulate size and dose,likely incorporating natural phenomena of speci f i city,critical thresholds,overstimulation,and desensitization.

When challenged with wear debris,three general cellular responses have been described,depending on particulate size.Particles＜150 nm are pinocytosed,particles 150 nm to 10 μm are phagocytosed,and particles＞20 μm induce multinucleated giant cell formation,with some overlap.6–7,31It should be noted that multinucleated giant cell formation and activity are often not analyzed in vitro,such as in the study by Green et al.38described above,due to long incubation time and unique culture requirements.Taking this into account,it quickly becomes evident why larger particles elicited no immediate osteolytic reaction in that study.The overall immune response to UHMWPE particles has been characterized as a foreign body reaction,marked by granulomatous chronic in f l ammation.7,31

INNATE IMMUNE RESPONSE

Although cells of monocytic lineage dominate in the pathogenesis of osteolysis,numerous cell types and in f l ammatory mediators have been implicated,summarized in Tables 1 and 2,respectively.Indicative of the innateimmune system,NALP3 in f l ammasome,nuclear factor-κB (NF-κB),TNF-α,and IL-1β activation are signi f i cant to this response.5–8,22,31Pathogenesis is diverse and multifactorial, but is ultimately driven by increased osteoclastogenesis, proin f l ammatory enzymatic bone resorption,and decreased osteoblastic activity.Although no secondary, adaptive immune response is implicated in UHMWPE wearinduced osteolysis,the innate response does occur in a sequential manner.The three main pathways favoring bone resorption mentioned above do not occur in isolation,but rather as a comprehensive process shifting normal bone metabolism in favor of catabolism,making a temporal presentation of osteolysis dif f i cult.Therefore, pathogenesis will be presented in a component-based system,exhibiting temporal progression as appropriate.

T-lymphocytes have been found in periprosthetic tissue with osteolysis but are generally detected in low numbers.40–41Furthermore,Pfp/Rag2 double-knockout mice(entirely lacking mature T and B lymphocytes with severe depletion of NK cell function)have been shown to develop osteolysis at similar rates to control mice with similar amounts of locally produced TNF-α and IL-1β.41However,a role has been proposed for lymphocytes in osteolysis,speci f i cally a hypersensitivity reaction to metalon-metal prostheses.6–7,9,40As this current study focuses on UHMWPE wear-induced osteolysis,these reactions are beyond the scope of this study.Therefore,lymphocytes and the adapative immune response will be excluded from any further discussion.

Table 1.Role of essential cells implicated in osteolysis pathogenesis

Cellular response

In order to fully comprehend the roles of monocytes, dendritic cells(DC),osteoclasts,osteoblasts,and f i broblasts in osteolysis,a basic understanding of physiologic bone metabolism must be realized.Bone is constantly under revision,formed by osteoblasts and broken down by osteoclasts under hormonal and paracrine regulation. When this homeostatic process is misbalanced in favor of catabolism,osteolysis results.Brie f l y,osteoclastogenesis is mediated by two growth factors:receptor activator ofNF-κB(RANK)ligand(RANKL)and macrophage colonystimulating factor.5–6,22,31,40,42RANKL is of the TNF superfamily;cytokines capable of inducing RANKL expression include TNF-α and IL-1β,among others.RANKL increases TNF-α production and TNF-α enhances NF-κB activation, forming a compounding and synergistic positive feedback loop.Stimulation of monocytes and osteoclast progenitors (OCP)by RANKL and macrophage colony-stimulating factor results in their fusion and differentiation into mature,multinucleated osteoclasts in tissue.Osteoblasts, which produce osteoprotegerin(OPG)or osteoclastogenesis inhibitory factor,are central to NF-κB regulation.OPGfunctions as an extracellular decoy receptor for RANKL, thereby inhibiting RANK stimulation and osteoclastogenesis.Finally,these factors,which in f l uence osteoblast/clast genesis,function,and survival,are mainly controlled by the interplay between parathyroid hormone,calcitonin,and estrogen under normal physiological conditions,summarized in Figure 1.Once fully differentiated,mature osteoclasts express tartrate-resistant acid phosphatase(TRAP) and cathepsin K(CATK),two enzymes essential to their lytic function.

Table 2.Role of key in f l ammatory mediators contributing to osteolysis

UHMWPE particles induce in f l ammation and stimulate macrophages by a variety of mechanisms.One such mechanism occurs through Toll-like receptor(TLR)activity. TLRs are expressed in many in f l ammatory cells,especially those of monocytic lineage,and their stimulation promotes phagocytosis and initiates an innate immune response mediated through NF-κB activation.43–45Classically,TLRs are stimulated by pathogen-or damage-associated molecular patterns in response to infection or tissue damage,allowing for an early in f l ammatory response. Maitra et al.46demonstrated that UHMWPE particles are comprised of alkane polymers capable of directly stimulating TLR2 and TLR1/2 in vitro,leading to their phagocytosis and subsequent immune activation.When recovered from osteolytic tissue,a majority of these alkane polymers were found to have undergone extensive carbonyl modi f i cation, indicative of oxidative damage likely mediated enzymatically by cells of monocytic lineage.A positive correlation was observed between amount of oxidation of alkane polymers and their af f i nity for TLR,with oxidized polymers exhibiting up to a 140-fold increase in binding af f i nity.In a subsequent study,44Maitra et al.observed that the endosomes of in f l ammatory in f i ltrates of periprosthetic tissue challenged with UHMWPE were engorged with alkane particles.The failure of the endosomal enzymes to degrade UHMWPE led to an increase in endosome compartment size,number,and fusion,with some observed along the plasma membrane undergoing exocytosis.Unsurprisingly,necrotic cells were observed in the surrounding tissue,with UHMWPE particles,cathepsin,and collagen damage detected.This tissue injury generates heat shock proteins and other damage-associated molecular patterns,7,47further increasing TLR activation.Incubation with oxidized alkanes activated DCs,macrophages, monocytes,and osteoclasts,with each expressing an upregulation of surface major histocompatibility complex class II,B7–1,B7–2,and CD40 molecules.44Signi f i cantly, these cells exhibited an increase in TLR1 and TLR2 mRNA transcription,with the upregulation of IL-1,IL-6,IL-10,IL-12, TNF-α,and IFN-γ.These f i ndings present many implications for the immune response to UHMWPE wear,most importantly that UHMWPE is capable of inciting a nonspeci f i c and self-propagating innate immune response.47

Another important f i nding by Maitra et al.44in the previously described study is that TLR stimulation of monocytes and macrophages induced pro-IL-1β expression but not the release of mature IL-1β,the actions of which are summarized in Table 2.Instead,endosomal destabilization and NALP3 in f l ammasome activity have been characterized as mediators of IL-1β and IL-18 maturation and release.4,7,44,48–50NALP3,when activated,complexes with adapter protein PYCARD,leading to caspase-1 recruitment and activation.Caspase-1 subsequently cleaves pro-IL-1β and pro-IL-18 into their active forms,allowing for their secretion.DCs treated with UHMWPE particles in vitro expressed increased levels of caspase-1 and active IL-1β and IL-18,which were subsequently downregulated after cathepsin inhibition.44In demonstrating that NALP3 in f l ammasome activity was integral to the development of pneumoconiosis(a disease process also characterized by foreign body reaction),Cassel et al.50reported that in f l ammasome activation required reactive oxygen species generation and an ef f l ux of potassium.NALP3 in f l ammasome activation therefore occurs by two mechanisms,both of which are consistent with osteolysis: reactive oxygen species and other danger signal(ATP, urate,and so on)generation,7,48,50–51and cathepsin release.7,44When osteoclasts,macrophages,and DCs phagocytose UHMWPE particles＜10 μm,they are unable to degrade them,leading to endosomal instability and the subsequent spilling of cathepsin.7,44This damage undoubtedly releases both self and neighboring intracellular contents that likely signal NALP3 activation further,paralleling the f i ndings by Cassel et al.50Furthermore,as UHMWPE particles are released secondary to endosomal instability,they are likely re-phagocytosed by other activated cells, leading to a perpetual in f l ammatory cascade in the local periprosthetic environment.When challenged by larger UHMWPE particles＞20μm,multinucleated giant cells are formed that undergo“frustrated phagocytosis,”where UHMWPE is trapped near the cell surface,activating NADPH oxidases.7,51These oxidases generate reactive oxygen species contributing to NALP3 in f l ammasome activation.Coupled with TLR-induced cytokine transcription,NALP3 in f l ammasome and caspase-1 activity allow IL-1β and IL-18 to contribute to development of osteolysis, as illustrated in Figure 2.A take home point from NALP3 in f l ammasome activation and activity is again that a nonspeci f i c,self-propagating immune response is initiated, destroying natural tissue architecture in a local environment.Despite the in f l ammatory response described, detection of osteolysis remains challenging,expounded upon further in Detection and diagnosis section.

Although bone destruction is mainly regulated by local proin f l ammatory factors in a periprosthetic microenvironment,systemic macrophage/OCP involvement is reported. Ren et al.28continuously infused saline or UHMWPE particles into mice femora and injected reporter bioluminescent macrophages into tail veins.Upon noninvasive in vivo imaging,signi f i cantly increased reporter macrophages were detected in femora of mice infused with UHMWPE, and these macrophages were positively stained for TRAP and were associated with increased bone destruction.Wu et al.29found that peripheral monocytes in patients with AL demonstrated an increased frequency of the CD14+CD16+phenotype compared with controls.The CD14+CD16+phenotype was then correlated with increased periprosthetic tissue macrophage in f i ltration and pathology score,plasma TNF-α and IL-1β levels,and inducible TNF-α and IL-1β production after stimulation with UHMWPE particles,paralleling f i ndings of CD14+CD16+monocytes in rheumatoid arthritis.29Coupled with the f i ndings that TNF-α can increase CD16 expression52and precede CD16+monocyte expansion,29Wu et al.concluded that TNF-α and CD16 likely form an auto-ampli f i cation loop.Applied to the local,periprosthetic environment in osteolytic tissue, this relationship likely has signi f i cant implications.Yet again exemplifying self-propagation,cytokine and chemokine production lead to the increased systemic migration of OCP and a potent,proin f l ammatory macrophage phenotype,resulting in a positive feedback loop of bone destruction.

Sharing lineage with monocytes,DCs have a role in osteolysis pathogenesis paralleling that of their close relatives.Maitra et al.42conducted an in vivo study assessing DC function in a calvaria UHMWPE-induced osteolytic Csf1r knockout mouse model(profoundly de f icient in osteoclasts,tissue macrophages,and Langerhans cells)with compelling results.Csf1r-/-mice challenged with UHMWPE particles developed statistically signi f i cant osteolysis vs controls,and demonstrated peripheral DC recruitment exhibiting CATK expression and multinucleated giant cell formation around UHMWPE particles.Although DCs have been shown to contribute to osteoclastogenesis through cytokine production,7,42,45–46,53the f i ndings of Maitra et al.suggest DCs may yet have a more direct role in bone metabolism.While it should be noted that the robust DC response seen by Maitra et al.may have been exaggerated ex vacuo,that is,due to a lack of normal monocytic or resident macrophage-derived osteoclastogenic function,DCs likely function in conjunction with these cells under normal physiological conditions.Indeed, in response to UHMWPE particles,DCs have been demonstrated to in f i ltrate periprosthetic tissue,7,44support prosthetic synovial pseudomembrane formation,7produce TNF-α,IFN-γ,and IL-1,IL-6,and IL-12,44,46upregulate major histocompatibility complex class II expression,44,46and phagocytose UHMWPE particles.7,44Thus,DCs should be considered as extensions of monocytes in regards to function and possible therapeutic intervention.

Cytokine response

Although poorly understood,molecular pathways and targets of osteolysis are emerging.NF-κB,described as the master regulator of immune response,47stimulates osteoclastogenesis,31and is activated by RANKL,the production of which is increased by TNF-α and IL-1β.54Osteoclastogenesis has also been reported in isolated OCPs when treated with TNF-α.Although debated,direct TNF-α-induced osteoclastogenesis is likely mediated by a RANKL-dependent mechanism.31Lam et al.55cultured puri f i ed OCPs with TNF-αand macrophage colonystimulating factor and found that the OCPs failed to undergo osteoclastogenesis.When cells recovered frommarrow were exposed to RANKL,differentiation did occur, paralleling con f l icting f i ndings by other authors.56–57Upon addition of OPG to initiation of bone marrow culture,55this effect was abolished,suggesting RANKL-dependent TNF-αinduced osteoclastogenesis.When OCPs were treated with RANKL and TNF-α,TNF-α was found to augment osteoclast differentiation in a dose-dependent manner. This synergistic effect was so powerful that 1 ng·mL-1of TNF-α was suf f i cient to potentiate osteoclast differentiation at RANKL doses＜1%of that normally required for osteoclastogenesis.

Regarding mature osteoclasts,TNF-α activates osteoclasts independent of and similar in potency to RANKL,and also greatly augments RANKL-induced osteoclast activation.58Fuller et al.58treated osteoclasts harvested in vitro and in vivo with TNF-α and discovered a potent stimulation of actin ring formation(indicative of activation and bone resorptive capability)comparable to that induced by RANKL.When incubated with OPG,no inhibition of TNF-α-induced actin ring formation occurred, suggesting a RANKL-independent mechanism for osteoclast activation.Incubation with small amounts of TNF-α and RANKL exhibited a greatly synergistic response paralleling actin formation induced by RANKL alone at concentrations magnitudes higher.Lee et al.59treated osteoclasts with various factors in vitro and found that TNF-α,IL-1β,and RANKL promoted osteoclast survival.TNF-α inhibited apoptosis the strongest,and this inhibition was dependent on Akt and ERK phosphorylation.By enhancing osteoclast differentiation,activation,and survival often in concert with RANKL,TNF-α signi f i cantly contributes to the development of osteolysis.

IL-1 serves to collaborate with TNF-α.Wei et al.demonstrated that TNF-α increases IL-1 and IL-1 receptor(IL-1R) type I expression by murine marrow stromal cells,and that osteoclastogenesis induced by TNF-α was reduced～50% with IL-1R antagonism.60Moreover,TNF-induced RANKL gene expression was blunted in IL-1R-de f i cient cells,an effect not seen in control cells treated with active vitamin D(known activator of RANKL gene).TNF-α and IL-1 effects were mediated by p38-associated mitogen-activated protein kinases(MAPK).In addition,Wei et al.60incubated OCPs derived from wild-type and TNF receptor-de f i cient mice with and without RANKL to assess IL-1 function.No osteoclast differentiation occurred in cultures without RANKL.Contrastingly,cultures incubated with RANKL and increasing amounts of IL-1 demonstrated a dosedependent differentiation of osteoclasts.TNF receptor knockout had no bearing on these results.Thus,in addition to mediating the effects of TNF-α,IL-1 is also capable of directly stimulating osteoclastogenesis in the presence of low levels of RANKL.IL-1R and IL-18R signaling have been reported to activate NF-κB and MAPK,paralleling these if ndings.48A conclusion to be drawn is that while TNF-α,IL-1, and RANKL display cooperative synergism to promote osteoclast differentiation,they also maintain independence to mediate these proin fl ammatory effects.The result is a fail-safe mechanism in initiating an immune response,one that possesses the ability to sustain and propagate itself,as described in earlier sections.

DETECTION AND DIAGNOSIS

Detection of osteolysis at stages early enough to implement intervention is challenging.First,osteolysis is often asymptomatic or undiagnosed until the need for revision surgery.4,8,17,20Traditional imaging frequently underestimates the true amount of periprosthetic bone loss17and its sensitivity is dependent upon lesion location,61–62while the widespread implementation of newer radiographic techniques poses challenges of cost-effectiveness and radiation exposure.4In addition,metal artifact from arthroplasties has greatly hindered visualization of the periprosthetic interface and therefore diagnosis utilizing computed tomography(CT)and magnetic resonance imaging(MRI).61High-resolution three-dimensional CT (3D-CT)has been developed to provide a more sensitive and accurate method than plain radiograph for measuring the size and progression of periprosthetic lesions in patients suspected of having osteolysis;63–65however,the need for longitudinal studies underlines the signi f i cant radiation risk in the population at large.

In a cadaveric study,MRI has been reported to be 95% sensitive and 98%speci f i c,with mean error of actual lesion volumes of 1.4±2.4 cm3.61In addition,MRI has been demonstrated to be more effective than CT and plain f i lm in detecting lesions≤3 cm,but less accurate than CT in measuring lesion volume.62Multiple advances in imaging technique have greatly enhanced metal artifact reduction in MRI,66making it a reasonable option for osteolysis/AL surveillance.However,visualization in MRI is still problematic,artifact reduction is variable,evaluation of the acetabulum is obscured by the convex surface of the acetabular implant,66and dif f i culty in clinical correlation exists.Signi f i cantly,both MRI and 3D-CT cannot detect in f l ammation that occurs at the initial and early stages of osteolysis,leading to formation of osteolytic lesions.

There is compelling evidence that imaging techniques directly targeting in f l ammatory cells within osteolytic tissue could become great tools for the detection of particleinduced in f l ammation.In diagnosis of periprosthetic infection and AL after TJA,nuclear medicine techniques including bone scrintigraphy(triple phase bone scan), leukocyte scintigraphy(white blood cell scan or WBCS),and 18F-labeled f l uorodeoxyglucose(FDG)-positron emission tomography(PET)have gained considerableattention.67–74Triple phase bone scan,which is easily performed and accessible,has varying sensitivities and speci f i cities in the literature,but is generally considered sensitive but not speci f i c with an accuracy of 50%–70%.67–69,72,74WBCS utilizes in vitro or in vivo labeling techniques to compare radiotracer uptake in periprosthetic tissue with set reference points generally in the marrow.69,72,74While various combinations of techniques utilizing WBCS may demonstrate high sensitivity and speci f i city for infection(accuracy of over 80%),even being considered the gold standard by some,numerous pitfalls exist.WBCS is complex,expensive,time consuming, requires multiple visits to perform,dependent on patient marrow characteristics,and involves contact with blood products and reinjection(in vitro)or immunogenic antibodies(in vivo).Importantly,in regards to AL,WBCS mainly labels neutrophils,so is relatively insensitive to the largely macrophage-driven response.

FDG-PET,based off the premise of increased glucose metabolism in activated leukocytes,is advantageous in that it involves just one injection,has quick results,has high target to background ratio,and provides high resolution.69,72,74As such,the focus of FDG-PET studies lay in the differentiation of periprosthetic infection from AL,as both can clinically present similarly but have vastly differing treatments.67–74From high-quality reviews in the literature, sensitivities,speci f i cities,and accuracies for diagnosing infection in THA are generally reported to be roughly 85%, 90%,and 90%,respectively.69–70,73For TKA,these values are roughly 96%,77%,and 83%.69,73Variable values across the literature are attributable to divergent criteria for image interpretation and diagnosis,67–74while the decreased speci f i city of TKA may be accounted for by nonspeci f i c tracer uptake in the knee69or intense tracer uptake attributable to capsulitis/synovitis from AL.73Regarding THA,a group of researchers from the University Hospital of Aachen,Germany was able to achieve a sensitivity, speci f i city,and accuracy of 94%,95%,and 95%in assessing 92 prostheses for periprosthetic infection versus AL.68Their criterion for diagnosis was based off of f i ve basic FDG uptake patterns.FDG uptake in periprosthetic soft tissue correlated with infection,while increased FDG uptake near the femoral neck and in the whole prosthesis-bone interface of the acetabular cup or in wide parts of the prosthesis-bone interface of the femoral stem correlated with AL.With these and further advancements,PET seems a promising tool to diagnose and potentially treat osteolysis and AL.

Utilizing in vivo imaging,the f i rst report of systemic leukocyte recruitment in particle-induced in f l ammation was most likely published by Ren et al.75They injected cement particles into femoral cavity of nude mice and then intravenously administered luciferase-expressing macrophages,demonstrating signi f i cant accumulation of macrophages at the femoral site with particles.The results of this study indicate that modulation of signaling mechanisms governing leukocyte recruitment may contribute to the treatment of osteolysis.On the basis of the activation of NF-κB in in f l ammatory cells stimulated by wear particles, Takahashi et al.described the feasibility of NF-κB/luciferase transgenic mice for in vivo imaging of in f l ammation and osteolysis in calvariae loaded with PE particles,highlighting a useful tool for evaluating the ef f i cacy of treatments for particle-induced osteolysis.76

Recently,a polymeric nanocarrier system targeting in f l ammatory cells was revealed by a series of experiments performed by a group of researchers at the University of Nebraska,to be enriched at in f l amed sites with a few animal models.8,77–80The system makes use of watersoluble copolymers of N-(2-hydrocpropyl)methacrylamide (HPMA),that were originally designed for cancer chemotherapy due to the meritorious properties of the nanoparticles.These include an enhanced permeability and retention effect,water-solubility,low immunogenicity, and high stability.81–82While HPMA copolymers have been labeled with near-infrared dye 800CW and radioisotope125I for imaging purposes78,80and loaded with a drug dexamethasone for therapeutic intention,77–78it is anticipated that conjugates of these copolymers with other radioisotopes such as111In,99mTc,18F,and64Cu,and other drugs,will be explored in the future in order to achieve the clinical use of nanocarriers for early diagnosis and effective treatment of periprosthetic osteolysis.These nanocarriers are in contrast to FDG-labeled probes,which are not feasible for drug conjugation as they are too nonspeci f i c and lack durability.

Formyl peptide receptors are a group of proteins within the G-protein-coupled receptor family,and are primarily expressed on the surface of activated leukocytes.83Utilizing cinnamoyl-Phe-(D)-Leu-Phe-(D)-Leu-Phe-Lys(cFLFLF),we have developed an innovative platform technology for a series of tracers detecting in f l ammation,with modular designs including leukocyte recognition(antagonistic, synthetic peptide with high af f i nity),optimization of pharmacological properties(linker),and a molecular imaging module for appropriate label detection.Utilization of cFLFLF is based on the fact that it is a well-de f i ned,non-natural amino acid-containing synthetic peptide with high af f i nity for formyl peptide receptors,and has small molecular weight,water-soluble,and functionally inactive properties. The cFLFLF-PEG modules have been successfully utilized by us and others,84–85for building PET(DOTA-64Cu),86optical imaging(Cy5 and Cy7),87–88and MRI(DOTA-Gd)89probes,and have exhibited excellent imaging in a variety of in f l ammation models in animals.Noticeably,an in vitro experiment showed that the cFLFLF-PEG-Cy7 probehas speci f i c binding af f i nity to the cultured,murine macrophage cell line RAW264.7 stimulated by lipopolysaccharide (Figure 3).90Furthermore,the cFLFLF-PEG-64Cu probe has been employed to target macrophage activity in apolipoprotein E-de f i cient(ApoE-/-)mice with type 2 diabetes mellitus,91and in a chemically-induced osteoarthritic rat model.90Our next plan is to explore the feasibility of utilizing cFLFLF-PEG as a carrier of various imaging and therapeutic agents for animal models of periprosthetic osteolysis,with the ultimate goal of developing these agents for the early diagnosis and treatment of osteolysis in improving clinical outcomes.

The clinical implementation of in vivo imaging techniques provides diverse and unique challenges compared with other imaging modalities.Many of these challenges are related to the probes themselves.Probes should have high and rapid uptake,selectivity,the ability to reside in target tissues long enough to allow optimal imaging, ef f i cient clearance to improve target to non-target ratio, and the absence of adverse effects.In addition,probes should have low radiation or toxicity,ease of accessibility, long shelf life,ease of use,and acceptable cost.Finally,like other imaging techniques,standardizations for diagnosis and therefore ef f i cacy of these modules must be attained. Keeping these in mind,it quickly becomes evident why the synthesis of probes acceptable and feasible for human use is such a dif f i cult task.

TREATMENT

Medical treatment of osteolysis has faced many challenges to date:detection of disease at stages early enough to implement ef f i cacious intervention,quantitative outcome measure of treatment ef f i cacy,and either safe or targeted delivery of drugs with potentially devastating systemic side effects.8,21Agents studied for treatment of osteolysis are those utilized in other catabolic bone diseases,namely bisphosphonates,9,21corticosteroids,5,8TNF-α antagonists,5,9,21IL-1 antagonists,5,21IL-10 vectors,5,31and OPG vectors.5,31Bisphosphonates have proven unsuccessful in in f l ammatory conditions and clinically are generally not supported by the literature,92while systemic corticosteroids are avoided due to unwanted and morbid side effects.5Purdue et al.8linked dexamethasone to an HPMA copolymer and found that single dose tail vein injection into an osteolytic mouse model completely prevented osteolysis,paralleling f i ndings of a preliminary study in an arthritic rat model where arthritis was prevented for over four weeks.77In additional experiments,Purdue et al.8found that this sustained effect of drugs coupled to HPMA copolymers was due to their rapid,nonspeci f i c endocytic uptake and sequestration by in f l ammatory cells at sites of in f l ammation,the bene f i ts of which are extremely advantageous:HPMA copolymers are capable of quick localization with high selectivity and demonstrate high durability.TNF-α and IL-1 antagonists have variably demonstrated ef f i cacy,but come with unwanted immunosuppression.5,21Anti-cytokine(IL-10 and OPG)gene therapy has demonstrated promising results in animal models,but reluctance to implement viral gene therapy in humans still exists.5In addition,adenoviral vectors are commonly used,which have high immunogenicity and are warned against.5As in vitro gene transfer and subsequent transplantation into human subjects remains a distant possibility,in vivo viral gene therapy likely is not a reasonable or realistic solution,especially as osteolysis is a chronic disease process.

Recently,targeting RANK/RANKL has emerged as a potential therapeutic avenue.Denosumab(Amgen;Thousand Oaks,CA,USA),a monoclonal antibody againstRANKL,has recently been approved for use in bony metastasis,hypercalcemia of malignancy recalcitrant to bisphosphonates,and certain giant cell tumors.It is currently in phase II clinical trials regarding ef f i cacy in osteolysis.93Denosumab is mostly effective due to its antiresorptive effects,as bone alkaline phosphatase did not decrease until a month after injection,while bone turnover markers immediately decreased.9The f i nding that a human null mutation of RANKL results in osteopetrosis but not immunosuppression provides support for RANKL antagonism as therapeutic intervention,despite the central role of NF-κB in immune response.94

Additional support for targeting RANK/RANKL arrives from studies demonstrating inhibition of osteolysis by:treatment with methotrexate,95ursolic acid,96and triptolide97(RANKL-mediated),p38 suppression98(downstream signaling cascade induced by RANKL),and RANK small interfering RNA local injection.99Methotrexate is an interesting option in that its effects are mainly mediated by the adenosine A2Areceptor,which has many downstream effects.95In an in vivo,UHMWPE particle-induced osteolytic murine model, Mediero et al.95found that methotrexate treatment increased alkaline phosphatase+cells,OPG expression, and bone formation and density,and reduced RANKL expression,RANK/RANKL+cells,in f l ammatory in f i ltrate, TRAP+and CATK+osteoclasts,and osteolysis.Considering the lower risk for failure by AL in rheumatoid arthritis patients,100many of whom are likely on methotrexate, adenosine A2Areceptor agonism may provide an invaluable therapeutic option in osteolysis.Systemic side effects with methotrexate or adenosine receptor treatment again validate the utility of controlled,localized treatment,which are possible with newer in vivo imaging techniques.

PERSPECTIVE

Despite advances in material design of prostheses used in TJA,medical treatments must continue to be pursued due to the lack of long-term clinical data of newer prostheses and the plethora of arthroplasties already performed with those more classical.The increasing number of surgeries being performed on increasingly younger patients expounds this need for medical intervention.In f l ammatory cells of monocytic lineage dominate pathogenesis of osteolysis,and therefore are the natural target for chemotherapy.Historically,the main barriers to implementation of effective therapy have been detecting disease at stages early enough for effective intervention and averting unwanted and signi f i cant systemic side effects.In theory, this can be accomplished by one of two methods: designing a drug without signi f i cant systemic side effects, or navigating a delivery mechanism that allows for localized and selective drug dissemination without systemic side effects.For example,a RANKL antagonist is currently in clinical trials for use in osteolysis,and this shows some promise in that it impacts immunocompetence less than originally thought.More importantly,copolymers utilized in newer in vivo imaging techniques have demonstrated excellent utility in detecting osteolysis early and, through linkers,providing selective and localized treatment able to be followed over time.HPMA and our cFLFLF modules demonstrate promising examples.With high selectivity,drugs targeting any signi f i cant pathway discussed may prove bene f i cial in the treatment of osteolysis, including RANK,NALP3 in f l ammasome,TNF-α,or caspase-1 antagonism,among others.As osteolysis develops over a period of 5–10 years,it may be reasonable to utilize in vivo imaging at post-operative intervals in the order of years,f i rst screened at 5 years post-operatively.With early detection and selective therapy without signi f i cant side effects, osteolysis can be managed medically to decrease morbidity and improve outcome after TJA.

Competing interests

The authors declare no con f l ict of interest.

1 Ethgen O,Bruyère O,Richy F et al.Health-related quality of life in total hip and total knee arthroplasty.A qualitative and systematic review of the literature.J Bone Joint Surg Am 2004;86-A:963–974.

2 Singh JA.Epidemiology of knee and hip arthroplasty:a systematic review.Open Orthop J 2011;5:80–85.

3 Lim JBT,Chou CC,Yeo W et al.Comparison of patient quality of life scores and satisfaction after common orthopedic surgical interventions. Eur J Orthop Surg Traumatol 2015;25:1007–1012.

4 Beck RT,Illingworth KD,Saleh KJ.Review of periprosthetic osteolysis in total joint arthroplasty:an emphasis on host factors and future directions.J Orthop Res 2012;30:541–546.

5 Wooley PH,Schwarz EM.Aseptic loosening.Gene Ther 2004;11: 402–407.

6 Jiang Y,Jia T,Wooley PH et al.Current research in the pathogenesis of aseptic implant loosening associated with particulate wear debris.Acta Orthop Belg 2013;79:1–9.

7 Cobelli N,Scharf B,Crisi GM et al.Mediators of the in f l ammatory response to joint replacement devices.Nat Rev Rheumatol 2011;7:600–608.

8 Purdue PE,Levin AS,Ren K et al.Development of polymeric nanocarrier system for early detection and targeted therapeutic treatment of peri-implant osteolysis.HSS J 2013;9:79–85.

9 Looney RJ,Schwarz EM,Boyd A et al.Periprosthetic osteolysis:an immunologist’s update.Curr Opin Rheumatol 2006;18:80–87.

10 Harris WH.Wear and periprosthetic osteolysis:the problem.Clin Orthop Relat Res 2001;393:66–70.

11 Warth LC,Callaghan JJ,Liu SS et al.Thirty-f i ve-year results after Charnley total hip arthroplasty in patients less than f i fty years old. J Bone Joint Surg Am 2014;96:1814–1819.

12 Marshall A,Ries MD,Paprosky W;Implant Wear Symposium 2007 Clinical Work Group.How prevalent are implant wear and osteolysis, and how has the scope of osteolysis changed since 2000?J Am Acad Orthop Surg 2008;16 Suppl 1:S1–S6.

13 Kurtz S,Ong K,Lau E et al.Projections of primary and revision hip and knee arthroplasty in the United States from 2005 to 2030.J Bone Joint Surg Am 2007;89:780–785.

14 Kurtz SM,Lau E,Ong K et al.Future young patient demand for primary and revision joint replacement:national projections from 2010 to 2030.Clin Orthop Relat Res 2009;467:2606–2612.

15 Jacobs CA,Christensen CP,Greenwald AS et al.Clinical performance of highly cross-linked polyethylenes in total hip arthroplasty.J Bone Joint Surg Am 2007;89:2779–2786.

16 Saleh KJ,Wood K,Gafni A et al.Immediate surgery versus waiting list policy in revision total hip arthroplasty:an economic evaluation. J Arthroplasty 1997;12:1–10.

17 Saleh KJ,Thongtrangan I,Schwarz EM.Osteolysis:medical and surgical approaches.Clin Orthop Relat Res 2004;427:138–147.

18 Khatod M,Inacio M,Paxton EW et al.Knee replacement:epidemiology,outcomes,and trends in Southern California:17,080 replacements from 1995 through 2004.Acta Orthop 2008;79:812–819.

19 Oduwole KO,Molony DC,Walls RJ et al.Increasing f i nancial burden of revision total knee arthroplasty.Knee Surg Sports Traumatol Arthrosc 2010;18:945–948.

20 Engh CA Jr,Ho H,Padgett DE.The surgical options and clinical evidence for treatment of wear or corrosion occurring with THA or TKA.Clin Orthop Relat Res 2014;472:3674–3686.

21 Schwarz EM.Implant Wear Symposium 2007 Biologic Work Group. What potential biologic treatments are available for osteolysis?J Am Acad Orthop Surg 2008;16(Suppl 1):S72–S75.

22 Noordin S,Masri B.Periprosthetic osteolysis:genetics,mechanisms, and potential therapeutic interventions.Can J Surg 2012;55:408–417.

23 Chandran P,Azzabi M,Andrews M et al.Periprosthetic bone remodeling after 12 years differs in cemented and uncemented hip arthroplasties.Clin Orthop Relat Res 2012;470:1431–1435.

24 Liao YS,Greer K,Hanes M et al.Effects of Resin and Dose on Wear and Mechanical Properties of Cross-Linked Thermally Stabilized UHMWPE. Society for Biomaterials,the 7th World Biomaterials Congress:Sydney, NSW,Australia,2004.

25 Kuzyk PR,Saccone M,Sprague S et al.Cross-linked versus conventional polyethylene for total hip replacement:a meta-analysis of randomised controlled trials.J Bone Joint Surg Br 2011;93: 593–600.

26 Thomas GE,Simpson DJ,Mehmood S et al.The seven-year wear of highly cross-linked polyethylene in total hip arthroplasty:a doubleblind,randomized controlled trial using radiostereometric analysis. J Bone Joint Surg Am 2011;93:716–722.

27 McCalden RW,MacDonald SJ,Rorabeck CH et al.Wear rate of highly cross-linked polyethylene in total hip arthroplasty.A randomized controlled trial.J Bone Joint Surg Am 2009;91:773–782.

28 Ren PG,Irani A,Huang Z et al.Continuous infusion of UHMWPE particles induces increased bone macrophages and osteolysis.Clin Orthop Relat Res 2011;469:113–122.

29 Wu W,Zhang X,Zhang C et al.Expansion of CD14+CD16+peripheral monocytes among patients with aseptic loosening.In f l amm Res 2009; 58:561–570.

30 Sethi Rk,Neavyn MJ,Rubash HE et al.Macrophage response to cross-linked and conventional UHMWPE.Biomaterials 2003;24: 2561–2573.

31 Ingham E,Fisher J.The role of macrophages in osteolysis of total joint replacement.Biomaterials 2005;26:1271–1286.

32 Yadav CS,Kumar A.Tips and Tricks in Hip and Knee Arthroplasty:A Practical Approach.Jaypee Brothers Medical Publishers:New Delhi, India,2014.

33 Revell PA,Weightman B,Freeman MA et al.The production and biology of polyethylene wear debris.Arch Orthop Trauma Surg 1978;91: 167–181.

34 Mirra JM,Marder RA,Amstutz HC.The pathology of failed total joint arthroplasty.Clin Orthop Relat Res 1982;170:175–183.

35 Wilkinson JM,Hamer AJ,Stockley I et al..Polyethylene wear rate and osteolysis:critical threshold versus continuous dose-response relationship.J Orthop Res 2005;23:520–525.

36 Dowd JE,Sychterz CJ,Young AM et al.Characterization of long-term femoral-head-penetration rates.Association with and prediction of osteolysis.J Bone Joint Surg Am 2000;82-A:1102–1107.

37 Schmalzried TP,Jasty M,Harris WH.Periprosthetic bone loss in total hip arthroplasty.Polyethylene wear debris and the concept of the effective joint space.J Bone Joint Surg Am 1992;74:849–863.

38 Green TR,Fisher J,Matthews JB et al.Effect of size and dose on bone resorption activity of macrophages by in vitro clinically relevant ultra high molecular weight polyethylene particles.J Biomed Mater Res 2000; 53:490–497.

39 Green TR,Fisher J,Stone MH et al.Polyethylene particles of a'critical size'are necessary for the induction of cytokines by macrophages in vitro.Biomaterials 1998;19:2297–2302.

40 Purdue PE,Koulouvaris P,Nestor BJ et al.The central role of wear debris in periprosthetic osteolysis.HSS J 2006;2:102–113.

41 Taki N,Tatro JM,Nalepka JL et al.Polyethylene and titanium particles induce osteolysis by similar,lymphocyte-independent,mechanisms. J Orthop Res 2005;23:376–383.

42 Maitra R,Follenzi A,Yaghoobian A et al.Dendritic cell-mediated in vivo bone resorption.J Immunol 2010;185:1485–1491.

43 Doyle SE,O’Connell RM,Miranda GA et al.Toll-like receptors induce a phagocytic gene program through p38.J Exp Med 2004;199: 81–90.

44 Maitra R,Clement CC,Scharf B et al.Endosomal damage and TLR2 mediated in f l ammasome activation by alkane particles in the generation of aseptic osteolysis.Mol Immunol 2009;47:175–184.

45 Tamaki Y,Takakubo Y,Goto K et al.Increased expression of toll-like receptors in aseptic loose periprosthetic tissues and septic synovial membranes around total hip implants.J Rheumatol 2009;36:598–608.

46 Maitra R,Clement CC,Crisi GM et al.Immunogenecity of modi f i ed alkane polymers is mediated through TLR1/2 activation.PLoS One 2008;3:e2438.

47 Kandahari AM,Yang X,Dighe AS et al.Recognition of immune response for the early diagnosis and treatment of osteoarthritis. J Immunol Res 2015;2015:192415.

48 Lamkan f i M,Dixit VM.In f l ammasomes:guardians of cytosolic sanctity.Immunol Rev 2009;227:95–105.

49 StPierre CA,Chan M,Iwakura Y et al.Periprosthetic osteolysis:characterizing the innate immune response to titanium wear-particles. J Orthop Res 2010;28:1418–1424.

50 Cassel SL,Eisenbarth SC,Iyer SS et al.The Nalp3 in f l ammasome is essential for the development of silicosis.Proc Natl Acad Sci USA 2008; 105:9035–9040.

51 O’Neill LA.Immunology.How frustration leads to in f l ammation. Science 2008;320:619–620.

52 Skinner NA,MacIsaac CM,Hamilton JA et al.Regulation of Toll-like receptor(TLR)2 and TLR4 on CD14dimCD16+monocytes in response to sepsis-related antigens.Clin Exp Immunol 2005;141: 270–278.

53 Cang D,Guo K,Zhao F.Dendritic cells enhance UHMWPE wear particle-induced osteoclast differentiation of macrophages.J Biomed Mater Res A 2015;103:3349–3354.

54 Hofbauer LC,Schoppet M.Clinical implications of the osteoprotegerin /RANKL/RANK system for bone and vascular diseases.JAMA 2004; 292:490–495.

55 Lam J,Takeshita S,Barker JE et al.TNF-alpha induces osteoclastogenesis by direct stimulation of macrophages exposed to permissive levels of RANK ligand.J Clin Invest 2000;106:1481–1488.

56 Kobayashi K,Takahashi N,Jimi E et al.Tumor necrosis factor alpha stimulates osteoclast differentiation by a mechanism independent of the ODF/RANKL-RANK interaction.J Exp Med 2000;191: 275–286.

57 Azuma Y,Kaji K,Katogi R et al.Tumor necrosis factor-alpha induces differentiation of and bone resorption by osteoclasts.J Biol Chem 2000; 275:4858–4864.

58 Fuller K,Murphy C,Kirstein B et al.TNFalpha potently activates osteoclasts,through a direct action independent of and strongly synergistic with RANKL.Endocrinology 2002;143:1108–1118.

59 Lee SE,Chung WJ,Kwak HB et al.Tumor necrosis factor-alpha supports the survival of osteoclasts through the activation of Akt and ERK. J Biol Chem 2001;276:49343–49349.

60 Wei S,Kitaura H,Zhou P et al.IL-1 mediates TNF-induced osteoclastogenesis.J Clin Invest 2005;115:282–290.

61 Weiland DE,Walde TA,Leung SB et al.Magnetic resonance imaging in the evaluation of periprosthetic acetabular osteolysis:a cadaveric study.J Orthop Res 2005;23:713–719.

62 Walde TA,De Weiland,Leung SB et al.Comparison of CT,MRI,and radiographs in assessing pelvic osteolysis:a cadaveric study.Clin Orthop Relat Res 2005;437:138–144.

63 Howie DW,Neale SD,Stamenkov R et al.Progression of acetabular periprosthetic osteolytic lesions measured with computed tomography. J Bone Joint Surg Am 2007;89:1818–1825.

64 Stamenkov RB,Howie DW,Neale SD et al.Distribution of periacetabular osteolytic lesions varies according to component design. J Arthroplasty 2010;25:913–919.

65 Howie DW,Neale SD,Martin W et al.Progression of periacetabular osteolytic lesions.J Bone Joint Surg Am 2012;94:e1171–e1176.

66 Fritz J,Lurie B,Miller TT et al.MR imaging of hip arthroplasty implants.Radiographics 2014;34:E106–E132.

67 Mumme T,Reinartz P,Alfer J et al.Diagnostic values of positron emission tomography versus triple-phase bone scan in hip arthroplasty loosening.Arch Orthop Trauma Surg 2005;125:322–329.

68 Reinartz P,Mumme T,Hermanns B et al.Radionuclide imaging of the painful hip arthroplasty:positron-emission tomography versus triple-phase bone scanning.J Bone Joint Surg Br 2005;87: 465–470.

69 Reinartz P.FDG-PET in patients with painful hip and knee arthroplasty:technical breakthrough or just more of the same.Q J Nucl Med Mol Imaging 2009;53:41–50.

70 Zoccali C,Teori G,Salducca N.The role of FDG-PET in distinguishing between septic and aseptic loosening in hip prosthesis:a review of literature.Int Orthop 2009;33:1–5.

71 Chacko TK,Zhuang H,Stevenson K et al.The importance of the location of f l uorodeoxyglucose uptake in periprosthetic infection in painful hip prostheses.Nucl Med Commun 2002;23:851–855.

72 Love C,Marwin SE,Palestro CJ.Nuclear medicine and the infected joint replacement.Semin Nucl Med 2009;39:66–78.

73 Zhuang H,Yang H,Alavi A.Critical role of 18F-labeled f l uorodeoxyglucose PET in the management of patients with arthroplasty.Radiol Clin North Am 2007;45:711–718.

74 Palestro CJ.Nuclear medicine and the failed joint replacement:Past, present,and future.World J Radiol 2014;6:446–458.

75 Ren PG,Lee SW,Biswal S et al.Systemic traf f i cking of macrophages induced by bone cement particles in nude mice.Biomaterials 2008;29: 4760–4765.

76 Takahashi K,Onodera S,Tohyama H et al.In vivo imaging of particle-induced in f l ammation and osteolysis in the calvariae of NF-κB/luciferase transgenic mice.J Biomed Biotechnol 2011;2011. pii:727063.

77 Quan LD,Purdue PE,Liu XM et al.Development of a macromolecular prodrug for the treatment of in f l ammatory arthritis:mechanisms involved in arthrotropism and sustained therapeutic ef f i cacy.Arthritis Res Ther 2010;12:R170.

78 Quan LD,Yuan F,Liu XM et al.Pharmacokinetic and biodistribution studies of N-(2-hydroxypropyl)methacrylamide copolymerdexamethasone conjugates in adjuvant-induced arthritis rat model. Mol Pharm 2010;7:1041–1049.

79 Ren K,Purdue PE,Burton L et al.Early detection and treatment of wear particle-induced in f l ammation and bone loss in a mouse calvarial osteolysis model using HPMA copolymer conjugates.Mol Pharm 2011; 8:1043–1051.

80 Ren K,Dusad A,Zhang Y et al.Early diagnosis of orthopedic implant failure using macromolecular imaging agents.Pharm Res 2014;31: 2086–2094.

81 Matsumura Y,Maeda H.A new concept for macromolecular therapeutics in cancer chemotherapy:mechanism of tumoritropic accumulation of proteins and the antitumor agent smancs.Cancer Res 1986;46 (Pt 1):6387–6392.

82 Lammers T.Improving the ef f i cacy of combined modality anticancer therapy using HPMA copolymer-based nanomedicine formulations. Adv Drug Deliv Rev 2010;62:203–230.

83 Migeotte I,Communi D,Parmentier M.Formyl peptide receptors:a promiscuous subfamily of G protein-coupled receptors controlling immune responses.Cytokine Growth Factor Rev 2006;17:501–519.

84 Xiao L,Zhang Y,Liu Z et al.Synthesis of the Cyanine 7 labeled neutrophil-speci f i c agents for noninvasive near infrared f l uorescence imaging.Bioorg Med Chem Lett 2010;20:3515–3517.

85 Mott TM,Johnston RK,Vijayakumar S et al.Monitoring therapeutic treatments against Burkholderia infections using imaging techniques. Pathogens 2013;2:383–401.

86 Locke LW,Chordia MD,Zhang Y et al.A novel neutrophil-speci f i c PET imaging agent:cFLFLFK-PEG-64Cu.J Nucl Med 2009;50:790–797. 87 Xiao L,Zhang Y,Berr SS et al.A novel near-infrared f l uorescence imaging probe for in vivo neutrophil tracking.Mol Imaging 2012;11: 372–382.

88 Zhou J,Tsai YT,Weng H et al.Real-time detection of implantassociated neutrophil responses using a formyl peptide receptortargeting NIR nanoprobe.Int J Nanomedicine 2012;7:2057–2068.

89 Stasiuk GJ,Smith H,Wylezinska-Arridge M et al.Gd3+cFLFLFK conjugate for MRI:a targeted contrast agent for FPR1 in in f l ammation. Chem Commun(Camb)2013;49:564–566.

90 Yang X,Chordia MD,Du X et al.Targeting formyl peptide receptor 1 of activated macrophages to monitor in f l ammation of experimental osteoarthritis in rat.J Orthop Res 2015;doi:10.1002/jor.23148[Epub ahead of print].

91 Zhang Y,Kundu B,Zhong M et al.PET imaging detection of macrophages with a formyl peptide receptor antagonist.Nucl Med Biol 2015; 42:381–386.

92 Smith RL,Schwarz EM.Are biologic treatments a potential approach to wear-and corrosion-related problems?Clin Orthop Relat Res 2014; 472:3740–3746.

93 Clinical Trials.U.S.NIH.＜clinicaltrials.gov＞.

94 Sobacchi C,Frattini A,Guerrini MM et al.Osteoclast-poor human osteopetrosis due to mutations in the gene encoding RANKL.Nat Genet 2007;39:960–962.

95 Mediero A,Perez-Aso M,Wilder T et al.Brief report:methotrexate prevents wear particle-induced in f l ammatory osteolysis in mice via activation of adenosine A2A receptor.Arthritis Rheumatol 2015;67: 849–855.

96 Jiang C,Xiao F,Gu X et al.Inhibitory effects of ursolic acid on osteoclastogenesis and titanium particle-induced osteolysis are mediated primarily via suppression of NF-κB signaling.Biochimie 2015;111: 107–118.

97 Huang J,Zhou L,Wu H et al.Triptolide inhibits osteoclast formation, bone resorption,RANKL-mediated NF-κB activation and titanium particle-induced osteolysis in a mouse model.Mol Cell Endocrinol 2015; 399:346–353.

98 Tian B,Jiang T,Shao Z et al.The prevention of titanium-particleinduced osteolysis by OA-14 through the suppression of the p38 signaling pathway and inhibition of osteoclastogenesis.Biomaterials 2014; 35:8937–8950.

99 Cordova LA,Trichet V,Escriou V et al.Inhibition of osteolysis and increase of bone formation after local administration of siRNA-targeting RANK in a polyethylene particle-induced osteolysis model. Acta Biomater 2015;13:150–158.

100 Rub-Sorensen C,Pedersen AB,Johnsen SP et al.Survival of primary total hip arthroplasty in rheumatoid arthritis patients.Acta Orthop 2010; 81:60–65.

101 Vermes C,Roebuck KA,Chandrasekaran R.Particulate wear debris activates protein tyrosine kinases and nuclear factor kappaB,which down-regulates type I collagen synthesis in human osteoblasts.J Bone Miner Res 2000;15:1756–1765.

102 Chiu R,Ma T,Smith RL et al.Ultrahigh molecular weight polyethylene wear debris inhibits osteoprogenitor proliferation and differentiation in vitro.J Biomed Mater Res A 2009;89:242–247.

103 Atkins GJ,Welldon KJ,Holding CA et al.The induction of a catabolic phenotype in human primary osteoblasts and osteocytes by polyethylene particles.Biomaterials 2009;30:3672–3681.

104 Hofbauer LC,Lacey DL,Dunstan CR et al.Interleukin-1beta and tumor necrosis factor-alpha,but not interleukin-6,stimulate osteoprotegerin ligand gene expression in human osteoblastic cells.Bone 1999;25: 255–259.

105 Kimble RB,Srivastava S,Ross FP et al.Estrogen de f i ciency increases the ability of stromal cells to support murine osteoclastogenesis via an interleukin-1 and tumor necrosis factor-mediated stimulation of macrophage colony-stimulating factor production.J Biol Chem 1996; 271:28890–28897.

106 Sakai H,Jingushi S,Shuto T et al.Fibroblasts from the inner granulation tissue of the pseudocapsule in hips at revision arthroplasty induce osteoclast differentiation,as do stromal cells.Ann Rheum Dis 2002;61: 103–109.

107 Koreny T,Tunyogi-Csapo M,Gai I et al.The role of fi broblasts and fi broblast-derived factors in periprosthetic osteolysis.Arthritis Rheum 2006;54:3221–3232.

108 Bondeson K,Blom AB,Wainwright S et al.The role of synovial macrophages and macrophage-produced mediators in driving in f l ammatory and destructive responses in osteoarthritis.Arthritis Rheum 2010; 62:647–657.

109 Nawrocki B,Polette M,Burlet H et al.Expression of gelatinase A and its activator MT1-MMP in the in f l ammatory periprosthetic response to polyethylene.J Bone Miner Res 1999;14:288–294.

110 Yu X,Huang Y,Collin-Osdoby P et al.CCR1 chemokines promote the chemotactic recruitment,RANKL development,and motility of osteoclasts and are induced by in f l ammatory cytokines in osteoblasts.J Bone Miner Res 2004;19:2065–2077.

111 Yoshitake F,Itoh S,Narita H et al.Interleukin-6 directly inhibits osteoclast differentiation by suppressing receptor activator of NF-kappaB signaling pathways.J Biol Chem 2008;283:11535–11540.

112 DeHeer DH,Engels JA,DeVries AS et al.In situ complement activation by polyethylene wear debris.J Biomed Mater Res 2001;54:12–19.

113 Mangham DC,Scoones DJ,Drayson MT.Complement and the recruitment of mononuclear osteoclasts.J Clin Pathol 1993;46:517–521. 114 Takei I,Takagi M,Santavirta S et al.Messenger ribonucleic acid expression of 16 matrix metalloproteinases in bone-implant interface tissues of loose arti f i cial hip joints.J Biomed Mater Res 2000;52:613–620. 115 Takagi M,Konttinen YT,Santavirta S et al.Extracellular matrix metalloproteinases around loose total hip prostheses.Acta Orthop Scand 1994;65:281–286.

This work is licensed under a Creative Commons Attribution 4.0 International License.The images or other third party material in this article are included in the article’s Creative Commons license,unless indicated otherwise in the credit line;if the material is not included under the Creative Commons license,users will need to obtain permission from the license holder to reproduce the material.To view a copy of this license,visit http://creativecommons.org/licenses/by/4.0/

©The Author(s)2016

Research(2016)4,16014;

10.1038/boneres.2016.14;published online:12 July 2016

1Department of Orthopaedic Surgery,University of Virginia,Charlottesville,VA,USA and2Department of Radiology and Medical Imaging, University of Virginia,Charlottesville,VA,USA

Correspondence:Quanjun Cui(qc4q@hscmail.mcc.virginia.edu)

Received:22 November 2015;Revised:8 May 2016;Accepted:13 May 2016